Literature DB >> 1182804

Fibrinolytic activity in a human fibrosarcoma cell line and evidence for the induction of plasminogen activator secretion during tumor formation.

P A Jones, W E Laug, W F Benedict.   

Abstract

Seven clones were isolated from the HT1080 human fibrosarcoma cell line using a fibrinagarose overlay technique. Three of these clones induced lysis of the fibrin overlay, whereas four did not. The extracellular and intracellular levels of protease were then measured using 125I-fibrin plates incubated with acid-treated human serum. The extracellular protease can be directly assayed in the medium from cells incubated with 10% fetal calf serum. Although there were large differences in the amounts of protease secreted by these two sets of clones, the intracellular levels of protease were similar. No significant differences were found between the abilities of the cells to grow in soft agar or as tumors in immunosuppressed hamsters. However, cells grown from tumors derived from all the low secretors of protease showed an increase in the amount of protease secreted. It appeared, therefore, that the secretion of protease might be selected for or induced during tumor growth. Further detailed studies with one of the low secreting clones (clone E) suggested an inductive rather than a selective mechanism for this increase in extracellular plasminogen activator.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1182804     DOI: 10.1016/0092-8674(75)90015-x

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  27 in total

1.  Distinguishable transformation-defective phenotypes among temperature-sensitive mutants of Rous sarcoma virus.

Authors:  D Becker; R Kurth; D Critchley; R Friis; H Bauer
Journal:  J Virol       Date:  1977-03       Impact factor: 5.103

2.  Loss of mouse chromosomes in somatic cell hybrids between HT-1080 human fibrosarcoma cells and mouse peritioneal macrophages.

Authors:  C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1976-09       Impact factor: 11.205

3.  Direct fluorescent assay of urokinase and plasminogen activators of normal and malignant cells: kinetics and inhibitor profiles.

Authors:  M Zimmerman; J P Quigley; B Ashe; C Dorn; R Goldfarb; W Troll
Journal:  Proc Natl Acad Sci U S A       Date:  1978-02       Impact factor: 11.205

4.  Lack of correlation between tumorigenicity and level of plasminogen activator in fibroblasts transformed by Rous sarcoma virus.

Authors:  B A Wolf; A R Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  1978-10       Impact factor: 11.205

5.  Proteolytic and metastatic activities of clones derived from a methylcholanthrene-induced murine fibrosarcoma.

Authors:  M E McLaughlin; I E Liener; N Wang
Journal:  Clin Exp Metastasis       Date:  1983 Oct-Dec       Impact factor: 5.150

6.  Differences in intracellular distribution of plasminogen activator in growing, confluent, and transformed 3T3 cells.

Authors:  S Jaken; P H Black
Journal:  Proc Natl Acad Sci U S A       Date:  1979-01       Impact factor: 11.205

7.  Transformation phenotype of polyoma virus-transformed rat fibroblasts: plasminogen activator production is modulated by the growth state of the cells and regulated by the expression of an early viral gene function.

Authors:  B Perbal
Journal:  J Virol       Date:  1980-08       Impact factor: 5.103

8.  Distinct transformation phenotypes induced by polyoma virus and simian virus 40 in rat fibroblasts and their control by an early viral gene function.

Authors:  B Perbal; M Rassoulzadegan
Journal:  J Virol       Date:  1980-02       Impact factor: 5.103

9.  The fibrinolytic system. A key to tumor metastasis?

Authors:  J M Malone; S L Wangensteen; W S Moore; K Keown
Journal:  Ann Surg       Date:  1979-09       Impact factor: 12.969

10.  Plasminogen activator induction and platelet aggregation by phorbol and some of its derivatives: correlation with skin irritancy and tumor-promoting activity.

Authors:  P J Brynes; R Schmidt; E Hecker
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.